Date: 2011-09-12
Type of information: Subvention
Company: Psioxus Therapeutics (UK)
Investors: Wellcome Trust (UK)
Amount: £1.8 million (€2.08 million)
Funding type: award
Planned used: PsiOxus will use the funding from the Wellcome Trust to conduct a phase I/II clinical trial of ColoAd1 in patients with metastatic colorectal cancer, to determine the safety and tolerability of the virus. Future studies are also planned in patients with other solid tumour types, including primary hepatocellular cancer and ovarian cancer.
Others: PsiOxus Therapeutics has received a Translation Award from the Wellcome Trust valued at up to £1.8 million. The funding will support clinical development of a virus that attacks cancer cells (the oncolytic virus ColoAd1 for the systemic treatment of metastatic cancer) with clinical trials expected to begin in early 2012. This is the second product PsiOxus has entering the clinic. Psioxus is also developing a small molecule treatment for Cachexia, a wasting syndrome associated with cancer and other serious chronic diseases that results in significant unintended weight loss. The product, MT-102, is currently in phase II clinical development.
Therapeutic area: Cancer - Oncology
